Jefferies Group's CDTX Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 766,520 shares of Cidara Therapeutics, Inc. (CDTX) worth $169.32 M, representing 0.87% of the portfolio. First purchased in 2025-Q2, this short-term holding has been held for 3 quarters.
Based on 13F filings, Jefferies Group has maintained this position in CDTX for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 401,520 shares. Largest reduction occurred in Q3 2025, reducing 85,000 shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's Cidara Therapeutics (CDTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Cidara Therapeutics (CDTX) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2025 | +450,000 | New Buy | 450,000 | $48.71 |
| Q3 2025 | -85,000 | Reduce 18.89% | 365,000 | $95.76 |
| Q4 2025 | +401,520 | Add 110.01% | 766,520 | $220.89 |
Jefferies Group's Cidara Therapeutics Investment FAQs
Jefferies Group first purchased Cidara Therapeutics, Inc. (CDTX) in Q2 2025, acquiring 450,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held Cidara Therapeutics, Inc. (CDTX) for 3 quarters since Q2 2025.
Jefferies Group's largest addition to Cidara Therapeutics, Inc. (CDTX) was in Q2 2025, adding 450,000 shares worth $21.92 M.
According to the latest 13F filing for Q4 2025, Jefferies Group's firm, Jefferies Financial Group Inc., owns 766,520 shares of Cidara Therapeutics, Inc. (CDTX), valued at approximately $169.32 M.
As of the Q4 2025 filing, Cidara Therapeutics, Inc. (CDTX) represents approximately 0.87% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in Cidara Therapeutics, Inc. (CDTX) was 766,520 shares, as reported at the end of Q4 2025.